SCHEMBL7530787

SCHEMBL7530787

CCCNc1cc(C)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.45
TDP1 Q9NUW8 1/20 0.40
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
DHFR P00374 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NR4A2 P43354 1/20 0.38
HTR1A P08908 2/20 0.38
ADRA1D P25100 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CISD1 Q9NZ45 1/20 0.37
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18893491 0.85 LMNA (0.45) CNR2RAB9ANR4A2HTR1AADRA1D
SCHEMBL12895633 0.84 PDK1 (0.41) TDP1PDK1PDK2PDK3PDK4
SCHEMBL7535112 0.82 POLB (0.47) TDP1HTR1AGAASMN1; SMN2IDO1
SCHEMBL7536862 0.80 GUCY1A1 (0.51) CNR2HTR1AADRA1DADRA1AADRA1B
Hydrochloric Acid SCHEMBL21248268 0.78 GUCY1A1 (0.50) CNR2KDM4EALDH1A1GAARAPGEF4
SCHEMBL10181982 0.78 HTT (0.48) TDP1KDM4EALDH1A1SMN1; SMN2CYP2C9
SCHEMBL14027366 0.77 CNR2 (0.39) CNR2HTR1AADRA1DADRA1AADRA1B
SCHEMBL3634658 0.77 TDP1 (0.45) CNR2TDP1NPC1RAB9AHTR1A
SCHEMBL20207677 0.77 SMN1; SMN2 (0.42) CNR2DHFRNPC1RAB9AHTR1A
SCHEMBL28091170 0.77 IDO1 (0.51) TDP1NPC1RAB9AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them FONTAINE EVELYNE (FR) 2002-09-26 US disclosed
EP-0934290-B1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2002-04-17 EP disclosed
US-6344470-B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same SANOFI-SYNTHELABO (FR) 2002-02-05 US disclosed
EP-0934290-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-08-11 EP disclosed
WO-1998015543-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them CRHR1, ADRA1D, ADRB1 CNR2 59/4885TDP1 4512/4885PDK1 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.